Review
doi: 10.1007/BF01525983.
The immunobiological effects of interleukin-2 in vivo
Affiliations
- PMID: 7954522
- PMCID: PMC11038771
- DOI: 10.1007/BF01525983
Item in Clipboard
Review
The immunobiological effects of interleukin-2 in vivo
Cancer Immunol Immunother.
1994 Oct.
No abstract available
Similar articles
-
[Prospects for cancer immunotherapy using interleukin-1(IL-1) and interleukin-2(IL-2)].Nihon Rinsho. 1983;41(4):868-74. Nihon Rinsho. 1983. PMID: 6350655 Review. Japanese. No abstract available.
-
Immunotherapy of cancer with interleukin-2 and lymphocytes (LAK or TIL).Pharmacol Res. 1992 Sep;26 Suppl 2:104-5. doi: 10.1016/1043-6618(92)90619-m. Pharmacol Res. 1992. PMID: 1409264 No abstract available.
-
Immunotherapy of human cancers with tumor-infiltrating lymphocytes and systemic infusions of interleukin-2.Cancer Invest. 1990;8(2):317-8. doi: 10.3109/07357909009017604. Cancer Invest. 1990. PMID: 2400959 No abstract available.
-
Immunotherapy of cancer using interleukin 2: current status and future prospects.Immunol Today. 1988 Feb;9(2):58-62. doi: 10.1016/0167-5699(88)91261-3. Immunol Today. 1988. PMID: 3076761 Review. No abstract available.
-
Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer.Cancer J Sci Am. 2000 Feb;6 Suppl 1:S2-7. Cancer J Sci Am. 2000. PMID: 10685650 Review. No abstract available.
Cited by
-
Interleukin-2 affects steroidogenesis and numbers of bovine ovarian granulosa cells but not thecal cellsin vitro.Endocrine. 1995 Dec;3(12):899-905. doi: 10.1007/BF02738895. Endocrine. 1995. PMID: 21153218
-
Immune reactions induced by interleukin-2 transfected colorectal cancer cells in vitro: predominant induction of lymphokine-activated killer cells.J Mol Med (Berl). 1996 Jan;74(1):43-9. doi: 10.1007/BF00202071. J Mol Med (Berl). 1996. PMID: 8834769
-
Treatment of metastatic renal cell carcinoma with subcutaneous interleukin 2: evidence for non-renal clearance of cytokines.Br J Cancer. 1997;75(12):1842-8. doi: 10.1038/bjc.1997.314. Br J Cancer. 1997. PMID: 9192992 Free PMC article.
-
Local therapy of cancer with free IL-2.Cancer Immunol Immunother. 2008 Jul;57(7):931-50. doi: 10.1007/s00262-008-0455-z. Cancer Immunol Immunother. 2008. PMID: 18256831 Free PMC article.
-
Immunomodulatory effects of intravenous BIS-1 F(ab')2 administration in renal cell cancer patients.Br J Cancer. 1995 Sep;72(3):795-9. doi: 10.1038/bjc.1995.414. Br J Cancer. 1995. PMID: 7669598 Free PMC article. Clinical Trial.
References
-
- Alexander JP, Kudoh S, Melsop KA, Hamilton TA, Edinger MG, Tubbs RR, Sica D, Tuason L, Klein E, Bukowski RM, Finke JH. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res. 1993;53:1380–1387. - PubMed
-
- Atzpodien J, Körfer A, Franks CR, Poliwoda H, Kirchner H. Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies. Lancet. 1990;335:1509–1512. - PubMed
-
- Azuma M, Cayabyab M, Phillips JH, Lanier LL. Requirements for CD28-dependent T cell-mediated cytotoxicity. J Immunol. 1993;150:2091–2101. - PubMed
-
- Baars JW, Hack CE, Wagstaff J, Eerenberg-Belmer AJM, Wolbink GJ, Thijs LG, Strack van Schijndel RJM, van der Vall HLJA, Pinedo HM. The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2. Br J Cancer. 1992;65:96–101. - PMC - PubMed
-
- Balch CM, Riley LB, Bae YJ, Salmeron MA, Platsoucas CD, von Eschenbach A, Itoh K. Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg. 1990;125:200–205. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources